Lv3
230 积分 2025-01-07 加入
ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
16小时前
待确认
Characteristics of myasthenia gravis in elderly patients: a retrospective study
1个月前
已完结
Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis
2个月前
已完结
Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy
3个月前
已完结
Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis
3个月前
已完结
Real-World experience with efgartigimod in patients with myasthenia gravis
3个月前
已完结
Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic crisis: A single-center case series
3个月前
已完结
The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis
3个月前
已完结
[Neonatal Fc receptor (FcRn)-A Novel Therapeutic Approach for Autoimmune Disease]
3个月前
已关闭
Targeted Treatments for Myasthenia Gravis in Children and Adolescents
3个月前
已完结
皖公网安备34019202002308
